株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

加齢黄斑変性症(AMD):パイプライン製品の分析

Age Related Macular Degeneration - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213105
出版日 ページ情報 英文 563 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
加齢黄斑変性症(AMD):パイプライン製品の分析 Age Related Macular Degeneration - Pipeline Review, H2 2016
出版日: 2016年12月14日 ページ情報: 英文 563 Pages
概要

加齢黄斑変性症 (AMD) は、50歳以上の人の失明原因で最も一般的なものです。黄斑に障害が生じ、中心視野が歪んだり、ぼやけたりします。素因として、年齢、喫煙、太陽光、遺伝などが挙げられます。盲点、目のかすみなどの症状が見られます。治療は、光線力学的療法、放射線療法、薬物療法 (抗血管新生薬など) があります。ビタミンや食習慣の改善も、有効性が証明されています。

当レポートでは、加齢黄斑変性症 (AMD) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

加齢黄斑変性症 (AMD) の概要

治療薬の開発

加齢黄斑変性症 (AMD) :企業で開発中の治療薬

加齢黄斑変性症 (AMD) :大学/機関で研究中の治療薬

加齢黄斑変性症 (AMD) :パイプライン製品の概況

加齢黄斑変性症 (AMD) :企業で開発中の製品

加齢黄斑変性症 (AMD) :大学/機関で研究中の製品

加齢黄斑変性症 (AMD) の治療薬開発に従事している企業

加齢黄斑変性症 (AMD) :治療薬の評価

薬剤プロファイル

加齢黄斑変性症 (AMD) :最近のパイプライン動向

加齢黄斑変性症 (AMD) :休止中のプロジェクト

加齢黄斑変性症 (AMD) :開発が中止された製品

加齢黄斑変性症 (AMD) :製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8804IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2016, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 33, 11, 109 and 31 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.Age Related Macular Degeneration.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Age Related Macular Degeneration Overview
  • Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics under Development by Companies
  • Age Related Macular Degeneration - Therapeutics under Investigation by Universities/Institutes
  • Age Related Macular Degeneration - Pipeline Products Glance
  • Age Related Macular Degeneration - Products under Development by Companies
  • Age Related Macular Degeneration - Products under Investigation by Universities/Institutes
  • Age Related Macular Degeneration - Companies Involved in Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics Assessment
  • Drug Profiles
  • Age Related Macular Degeneration - Dormant Projects
  • Age Related Macular Degeneration - Discontinued Products
  • Age Related Macular Degeneration - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Age Related Macular Degeneration, H2 2016
  • Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by AC Immune SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Aciont Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Alimera Sciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Allergan Plc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H2 2016
  • Age Related Macular Degeneration - Pipeline by Alteogen Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Amakem NV, H2 2016
  • Age Related Macular Degeneration - Pipeline by Amarna Therapeutics BV, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
  • Age Related Macular Degeneration - Pipeline by ANP Technologies Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Apexigen Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Benitec Biopharma Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by BioMAS Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Biophytis SAS, H2 2016
  • Age Related Macular Degeneration - Pipeline by BLR Bio LLC, H2 2016
  • Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Age Related Macular Degeneration - Pipeline by Caladrius Biosciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Catalyst Biosciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Cell Medica Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Charlesson LLC, H2 2016
  • Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Cipla Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Clanotech AB, H2 2016
  • Age Related Macular Degeneration - Pipeline by Clearside BioMedical Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Coherus BioSciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016
  • Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H2 2016
  • Age Related Macular Degeneration - Pipeline by Exonate Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by FirstString Research Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Formycon AG, H2 2016
  • Age Related Macular Degeneration - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Genentech Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Grupo Ferrer Internacional SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016
  • Age Related Macular Degeneration - Pipeline by Icon Bioscience Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Iconic Therapeutics Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Inception Sciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Innovent Biologics Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Intellect Neurosciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by International Stem Cell Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H2 2016
  • Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Kodiak Sciences Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Age Related Macular Degeneration - Pipeline by LeadArtis SL, H2 2016
  • Age Related Macular Degeneration - Pipeline by M's Science Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Mabion SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by MacuCLEAR Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by MeiraGTx Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Mitotech SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Mor Research Application Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Navigen Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Neovacs SA, H2 2016
  • Age Related Macular Degeneration - Pipeline by Neumedicines Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Neuroptis Biotech, H2 2016
  • Age Related Macular Degeneration - Pipeline by Novartis AG, H2 2016
  • Age Related Macular Degeneration - Pipeline by NovelMed Therapeutics Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ocular Therapeutix Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Omeros Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ophthotech Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016
  • Age Related Macular Degeneration - Pipeline by PanOptica Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Pfenex Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Pfizer Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Precision Ocular Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Promedior Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by pSivida Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by QLT Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by RegenxBio Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Retrotope Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Ribomic Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Samumed LLC, H2 2016
  • Age Related Macular Degeneration - Pipeline by SanBio Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Santen Pharmaceutical Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences LLC, H2 2016
  • Age Related Macular Degeneration - Pipeline by Stealth BioTherapeutics Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Sucampo Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
  • Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by TWi Pharmaceuticals Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Tyrogenex Inc, H2 2016
  • Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corp, H2 2016
  • Age Related Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Age Related Macular Degeneration - Dormant Projects, H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..1), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..2), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..3), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..4), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..5), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..6), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..7), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..8), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..9), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..10), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..11), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..12), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..13), H2 2016
  • Age Related Macular Degeneration - Dormant Projects (Contd..14), H2 2016
  • Age Related Macular Degeneration - Discontinued Products, H2 2016
  • Age Related Macular Degeneration - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Age Related Macular Degeneration, H2 2016
  • Number of Products under Development for Age Related Macular Degeneration - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top